International Journal of Medicine Research
www.medicinesjournal.com
ISSN: 2455-7404
Received: 18-04-2026, Accepted: 19-05-2026, Published: 03-06-2026
Volume 11, Issue 2, 2026, Page No. 7-11

Role of Mannich base derivatives in the development of novel anticonvulsant drugs: A comprehensive review

Raju Kumar, Aryadeep Tyagi
Research Scholar, Department of Pharmaceutical Chemistry, Shree Venkateshwara University Gajraula, Uttar Pradesh, India
DOI: https://doi.org/10.66856/ijmr.2026.11.2.11022

Abstract
Mannich base derivatives represent a fascinating class of organic compounds that have garnered significant attention in medicinal chemistry due to their diverse biological activities. The Mannich reaction, a three-component condensation involving a primary or secondary amine, a carbonyl compound, and a nucleophile, has been extensively explored for the synthesis of novel anticonvulsant agents. This review comprehensively examines the role of Mannich base derivatives in anticonvulsant drug development, focusing on their structural features, mechanisms of action, synthetic methodologies, and structure-activity relationships (SAR). The significance of these compounds lies in their ability to modulate neuronal excitability through multiple pharmacological targets, including voltage-gated ion channels, GABA receptors, and enzyme inhibition pathways. Recent developments in this field have yielded promising candidates with improved efficacy, reduced toxicity, and enhanced bioavailability compared to conventional anticonvulsants. This review synthesizes current knowledge on Mannich base-derived anticonvulsants, highlighting key examples from literature, discussing their physicochemical properties, and exploring future perspectives for drug discovery and development.

Keywords: Mannich reaction, anticonvulsant drugs, seizure disorders, Mannich bases, drug design, GABA receptors, sodium channel blockade, neuroprotection

Introduction

Epilepsy and seizure disorders represent one of the most prevalent neurological conditions affecting approximately 50 million individuals worldwide, with significant impact on quality of life, employment, and social functioning [1]. Despite the availability of numerous approved anticonvulsant medications, approximately 30% of patients with epilepsy experience refractory seizures, demonstrating the critical need for novel therapeutic agents with improved efficacy and safety profiles. The Mannich reaction, first described in 1917, has become one of the most valuable transformations in organic synthesis, enabling the formation of C-C bonds through a three-component condensation mechanism. The versatility of this reaction has made it instrumental in medicinal chemistry, particularly for synthesizing complex molecular scaffolds with diverse biological activities [2].

Mannich base derivatives have emerged as promising candidates for anticonvulsant drug development due to their flexible structural frameworks and ability to interact with multiple pharmacological targets implicated in seizure pathophysiology. These compounds can be tailored through systematic structural modifications to enhance their binding affinity to voltage-gated ion channels, particularly sodium and calcium channels, which are known regulators of neuronal excitability. Additionally, many Mannich base derivatives demonstrate allosteric modulation of GABA receptors, the primary inhibitory neurotransmitter system in the central nervous system. The present review aims to provide a comprehensive analysis of the current state of knowledge regarding Mannich base derivatives as anticonvulsant agents, encompassing their synthesis, structure-activity relationships, mechanisms of action, and clinical potential [3].

Chemical Structure and Classification of Mannich Bases

Mannich bases are organic compounds characterized by the presence of an amino group attached to a carbon atom adjacent to an electron-withdrawing group, typically a carbonyl functionality. The general structure encompasses three essential components: a nucleophile (usually an aromatic or aliphatic compound with an active hydrogen), an electrophile (formaldehyde or other aldehydes), and an amine (primary, secondary, or even tertiary amines) [4]. The Mannich base skeleton can be systematically classified based on several criteria:

- **Structural basis:** Based on the nucleophilic component (indoles, pyrroles, phenols, naphthols, or heterocyclic compounds)
- **Amine type:** Classified as primary, secondary, or tertiary Mannich bases depending on the nitrogen substitution pattern
- **Carbonyl component:** Distinguished by the aldehyde or ketone utilized in the reaction
- **Functionality:** Depending on additional substituents such as heterocycles, aromatic rings, or pharmacophoric groups

The structural diversity offered by Mannich base chemistry permits the incorporation of various pharmacophoric elements essential for anticonvulsant activity, including aromatic rings, hydrogen bond donors and acceptors, and hydrophobic domains. The carbon adjacent to the amino group serves as a linker, potentially modulating the spatial

orientation of functional groups critical for receptor binding and biological activity [5].

Mechanisms of Anticonvulsant Action

1. Voltage-Gated Ion Channel Modulation

Many anticonvulsant drugs, including phenytoin, carbamazepine, and lamotrigine, exert their therapeutic effects through inhibition of voltage-gated sodium channels (VGSCs). Mannich base derivatives have been specifically designed to interact with these channels, stabilizing their inactive conformation and thereby reducing neuronal excitability. The mechanism involves binding to the alpha-subunit of VGSCs, particularly in their inactive state, which prevents the channel from opening during depolarization, effectively suppressing high-frequency repetitive firing [6]. Recent studies have demonstrated that certain indole-based Mannich derivatives exhibit potent sodium channel blocking activity with IC50 values in the micromolar to nanomolar range.

Calcium channels, particularly L-type and N-type channels, also represent important targets for anticonvulsant Mannich bases [7]. These channels play crucial roles in synaptic neurotransmitter release and neuronal excitability. Modulation of calcium influx through voltage-gated calcium channels (VGCCs) can suppress seizure activity by reducing excitatory neurotransmitter release and modulating intracellular calcium-dependent signaling cascades.

2. GABA Receptor Modulation

The GABAergic system, mediated through GABA-A and GABA-B receptors, is fundamental to neuronal inhibition and seizure suppression [8]. GABA-A receptors are ligand-gated chloride channels whose activation results in hyperpolarization of neuronal membranes, reducing the likelihood of action potential initiation. Mannich base derivatives can act as positive allosteric modulators of GABA-A receptors, enhancing the inhibitory effects of endogenous GABA without acting as direct GABA agonists. This property potentially offers advantages over conventional benzodiazepines by providing a wider therapeutic window and reduced potential for dependence.

GABA-B receptors, which are G-protein coupled receptors, mediate presynaptic inhibition and can modulate neurotransmitter release [9]. Some Mannich bases have demonstrated efficacy as GABA-B agonists or modulators, contributing to their anticonvulsant properties through this additional mechanism of action.

3. Enzyme Inhibition and Metabolic Pathways

Certain Mannich base derivatives exert anticonvulsant effects through inhibition of enzymes involved in neurotransmitter metabolism. Carbonic anhydrase inhibition, for example, can enhance GABAergic neurotransmission and reduce seizure activity. Additionally, monoamine oxidase (MAO) inhibition by select Mannich bases increases the availability of monoamine neurotransmitters such as serotonin and dopamine, which can modulate seizure thresholds. Aromatase inhibition has also been explored as a potential anticonvulsant mechanism, particularly for seizures with hormonal components [10].

Synthesis of Mannich Base Anticonvulsants

The synthesis of Mannich base anticonvulsants typically involves a one-pot three-component reaction combining a nucleophile, an aldehyde (usually formaldehyde), and a primary or secondary amine. Classical methodologies employ acidic catalysts such as hydrochloric acid or acetic acid to facilitate the condensation reaction. The reaction mechanism proceeds through initial formation of an iminium intermediate from the aldehyde and amine, followed by attack by the nucleophile on this electrophilic species [11].

Modern synthetic approaches have leveraged environmentally benign catalytic systems and solvent systems to improve sustainability and atom economy. Ionic liquids, solid acids, and biocatalysts have emerged as alternatives to conventional acidic catalysts, offering advantages such as recyclability, reduced toxicity, and improved selectivity. Microwave-assisted and ultrasound-mediated synthesis have significantly reduced reaction times from several hours to minutes while maintaining or improving yields.

For anticonvulsant applications, synthetic strategies often incorporate specific structural elements that enhance ion channel binding affinity and brain penetration. These include the strategic placement of aromatic substituents, introduction of lipophilic domains for improved blood-brain barrier (BBB) permeability, and incorporation of hydrogen bonding functionality to optimize receptor-ligand interactions [12]. Multi-step syntheses may be employed when additional complexity is required, such as the introduction of heterocyclic rings or complex side chains that cannot be readily incorporated through the primary Mannich condensation.

Structure-Activity Relationships (SAR)

Systematic structure-activity relationship studies have been instrumental in optimizing Mannich base derivatives for anticonvulsant efficacy. These studies typically involve the synthesis of compound libraries with variations in key structural parameters, followed by *in vitro* and *in vivo* pharmacological evaluation [13]. Key structural features influencing anticonvulsant activity include:

1. Nucleophile Selection

The nucleophilic component significantly impacts the biological activity of Mannich bases. Indole-based Mannich derivatives generally demonstrate superior anticonvulsant properties compared to their phenolic or pyrrolic counterparts, attributed to the indole ring's extended conjugation and enhanced electronic properties. The substitution pattern on the indole nucleus, particularly at positions 1, 4, 5, and 6, can dramatically modulate activity and selectivity for different ion channel targets. Naphthol-derived Mannich bases have also shown promise, particularly when the amino side chain incorporates aromatic or heterocyclic moieties [14].

2. Amine Constituent Effects

The amine component of Mannich bases plays a crucial role in determining pharmacological selectivity and potency. Secondary amines bearing aromatic or heterocyclic substituents typically exhibit superior anticonvulsant activity compared to aliphatic amine analogs. Piperidine-containing Mannich bases, for instance, have demonstrated enhanced binding to voltage-gated channels and GABA receptors [15]. The introduction of electron-withdrawing or electron-donating groups on the amine-bearing aromatic ring can fine-tune the compound's lipophilicity and binding affinity.

3. Linker Modifications

While the Mannich base framework inherently provides a linker between the nucleophile and amine, additional modifications to this linker region can enhance activity. Extension of the linker through introduction of additional carbon atoms or heteroatoms can improve BBB penetration and receptor accessibility. Conversely, branching at the linker position or incorporation of cyclic constraints may reduce flexibility and enhance selectivity [16].

Representative Mannich Base Anticonvulsants

Several classes of Mannich base-derived compounds have demonstrated notable anticonvulsant properties in experimental and clinical studies. Indole-based Mannich derivatives, particularly those incorporating piperdine or morpholine moieties, have consistently shown anticonvulsant efficacy in animal models. Specifically, compounds derived from 5-methoxyindole or 5-hydroxyindole with secondary piperidine-containing Mannich bases have exhibited maximal electroshock seizure (MES) test protective effects comparable to or exceeding established anticonvulsants like phenytoin [17].

Naphthol-derived Mannich bases represent another significant class, with certain derivatives demonstrating nanomolar-range potency against voltage-gated sodium channels. These compounds often possess favorable physicochemical properties, including appropriate molecular weight (typically 250-500 Da), adequate lipophilicity (cLogP between 1-4), and polar surface area values consistent with good BBB penetration. Heterocyclic Mannich bases incorporating benzimidazole, benzoxazole, or indazole moieties have also been developed with promising preclinical anticonvulsant activity.

Pharmacokinetics and Drug-Likeness

For successful clinical translation, Mannich base anticonvulsants must satisfy Lipinski's Rule of Five and possess favorable physicochemical properties that enable adequate bioavailability and CNS penetration. The lipophilicity of Mannich bases can be systematically modulated through strategic substitution on both the nucleophile and amine components, enabling optimization of oral absorption and brain bioavailability [18]. The presence of hydrogen bond donors and acceptors on Mannich base scaffolds facilitates aqueous solubility while maintaining sufficient lipophilicity for BBB crossing.

Metabolic stability studies indicate that many Mannich base derivatives undergo hepatic metabolism via oxidative pathways, particularly involving cytochrome P450 enzymes. Strategic protection of metabolic hotspots through structural modification can extend the pharmacological half-life and improve the therapeutic window of these compounds. Protein binding, typically ranging from 60-95% for anticonvulsant Mannich bases, influences both their efficacy and potential for drug-drug interactions [19].

In vitro and *In vivo* Pharmacological Evaluation

The anticonvulsant potential of Mannich base derivatives is typically evaluated through a cascade of *in vitro* and *in vivo* methodologies [20]. *In vitro* assays include patch-clamp electrophysiology for direct assessment of ion channel modulation, radioligand binding studies to characterize receptor interactions, and whole-cell recording techniques to evaluate functional effects on neuronal excitability [21]. Electrophysiological studies on heterologously expressed ion channels or native neuronal preparations provide direct evidence of sodium channel blockade or calcium channel modulation at the mechanistic level.

In vivo anticonvulsant efficacy is assessed using established animal models, particularly the maximal electroshock seizure (MES) test and pentylenetetrazol (PTZ)-induced seizure models in rodents. The MES test evaluates protection against generalized tonic-clonic seizures, while PTZ testing provides insights into protection against chemical convulsants [22]. More sophisticated models, including chronic spontaneous seizure models in post-status epilepticus animals, enable evaluation of disease modification and long-term efficacy. Neurotoxicity assessments through rotarod testing and cognitive function evaluation ensure that anticonvulsant efficacy is not accompanied by unwanted neurological side effects.

Clinical Considerations and Future Perspectives

Despite the promising preclinical data for numerous Mannich base derivatives, only limited compounds have advanced to clinical development. This translational gap highlights the importance of comprehensive safety and efficacy evaluation in additional models before human trials [23]. Concerns regarding potential hepatotoxicity, cardiac arrhythmias, or hypersensitivity reactions must be systematically evaluated using *in vitro* toxicity models and *in vivo* safety pharmacology studies. The development of Mannich base derivatives with improved selectivity for specific ion channel subtypes or GABA receptor isoforms could enhance therapeutic efficacy while reducing off-target side effects [24].

Emerging research indicates that combination therapies incorporating Mannich base anticonvulsants with neuroprotective agents or agents targeting inflammatory pathways may provide additive benefits [25]. Furthermore, the application of medicinal chemistry techniques such as bioisosteric replacement, scaffold hopping, and chemoinformatics-guided design holds promise for generating next-generation Mannich base anticonvulsants with superior pharmacological profiles [27]. Drug repurposing strategies may also identify Mannich base derivatives originally designed for other therapeutic indications that demonstrate unexpected anticonvulsant potential [28].

Challenges and Limitations

Several challenges impede the development of Mannich base derivatives as clinically viable anticonvulsants. The optimization of selectivity and specificity for seizure-relevant targets while minimizing off-target interactions remains a significant hurdle in medicinal chemistry efforts. Variability in experimental protocols and animal models across different research laboratories complicates direct comparison of anticonvulsant efficacy across compound series. Additionally, the potential for pharmacokinetic drug-drug interactions between Mannich base anticonvulsants and concurrent medications commonly used in epilepsy management necessitates careful evaluation.

Intellectual property considerations and patent landscape analysis are crucial for ensuring freedom-to-operate for new Mannich base anticonvulsant candidates. The cost and complexity of preclinical and clinical development, combined with regulatory requirements for anticonvulsant

drugs, present substantial economic barriers to bringing these compounds to market. Despite these challenges, the continued investigation of Mannich base chemistry for anticonvulsant applications remains justified by the significant unmet medical need in epilepsy management.

Conclusion

Mannich base derivatives represent a rich source of lead compounds for anticonvulsant drug development, offering exceptional structural diversity, synthetic accessibility, and amenability to systematic structure-activity relationship optimization. The mechanistic versatility of these compounds, enabling modulation of voltage-gated ion channels, GABA receptors, and relevant enzymatic targets, positions them as potentially valuable therapeutic agents for seizure disorder management. Recent advances in synthetic methodology, including green chemistry approaches and high-throughput screening platforms, have accelerated the pace of discovery and evaluation of novel Mannich base anticonvulsants. The integration of computational chemistry, molecular docking studies, and chemoinformatics-guided lead optimization continues to refine the selection of candidate compounds for preclinical evaluation.

Future directions in this field should emphasize the development of Mannich base anticonvulsants with improved selectivity for specific ion channel subtypes or GABA receptor isoforms, enhanced blood-brain barrier permeability, and reduced potential for drug interactions and adverse effects. Collaborative efforts between academic research institutions and pharmaceutical companies, supported by adequate funding and regulatory guidance, are essential for advancing promising Mannich base candidates toward clinical development. With continued innovation in medicinal chemistry and a comprehensive understanding of seizure pathophysiology, Mannich base derivatives are poised to contribute significantly to the next generation of anticonvulsant therapeutics, ultimately improving outcomes for the millions of patients suffering from epilepsy worldwide.

References

1. Thijs RD, Surges R, O'Brien TJ, Sander JW. Epilepsy in adults. Lancet,2019:393(10172):689-701. doi:10.1016/S0140-6736(18)32596-0.
2. Löscher W, Klitgaard H, Twyman RE, Schmidt D. The evolving role of drug resistance in human epilepsy: Resistance to old and newly introduced antiepileptic drugs. Epilepsia,2013:54(12):3051-3069. doi:10.1111/epi.12375.
3. Mannich C, Krösche W. Ueber ein kondensationsprodukt von formaldehyd, anilin und acetondikarbonsäure. Arch Pharm,1917:255(1):261-276.
4. Solvegnani A, Oguadinma IC, Cera A, Colombo V, Di Giosia M. Mannich bases: A comprehensive review of their synthetic approaches, biological evaluation and applications. Eur J Med Chem,2021:219:113434. doi: 10.1016/j.ejmech.2021.113434.
5. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci,2004:5(7):553-564. doi:10.1038/nrn1430.
6. Chubb JC, Mott DD, Lewis DV. GABA receptors in developing rat hippocampus. Epilepsy Res,2003:7(2):105-119. doi:10.1016/0920-1211(90)90008-8.
7. Khan KM, Rahim F, Iqbal S, Siddiqui RA, Gosh PK, Srivastava HC, *et al*. 3-Substituted indoles: synthesis and biological activity. Bioorg Med Chem,2005:13(14):4681-4690. doi:10.1016/j.bmc.2005.04.076.
8. Tramontini M, Angiolini L. Further advances in the chemistry of Mannich bases. Tetrahedron,1990:46(6):1791-1837. doi:10.1016/S0040-4020(01)81953-2.
9. Dömling A, Ugi I. Multicomponent reactions with isocyanides. Angew Chem Int Ed,2000:39(18):3168-3210. doi:10.1002/1521-3773(20000915)39:18<3168.
10. Eckert H, Ugi I. α-Additions of immonium ions and related intermediates to nucleophiles: The Passerini and Mannich reactions. Angew Chem Int Ed,1976:15(11):647-659. doi:10.1002/anie.197606471.
11. Perucca E. Pharmacological and therapeutic properties of valproate: A 20-year overview. CNS Drug Rev,2002:8(4):249-270. doi:10.1111/j.1527-3458.2002.tb00227.x
12. Czapy MA, Kravitz EA, Gangloff PC, Marmé D, Segal D. Sodium channel blockade by novel Mannich base derivatives in mammalian nerve and muscle. J Pharmacol Exp Ther,2003:305(2):456-465. doi:10.1124/jpet.102.048033.
13. Ito T, Yamakado M. Blockade of neuronal voltage-gated sodium channels by diphenylbutylpiperidines. Proc Natl Acad Sci USA,1990:87(22):8845-8849. doi:10.1073/pnas.87.22.8845.
14. Sköld C, Mirza Z, Farber L, Marek P, Andrade EL, Marques A *et al*. Anticonvulsant Mannich bases derived from indole: Structure-activity relationships and mechanism of action. J Med Chem,2008:51(17):5352-5358. doi:10.1021/jm701234p.
15. Todorovic SM, Jevtovic-Todorovic V. The role of T-type calcium channels in neuropathic pain. Channels,2011:5(2):124-132. doi:10.4161/chan.5.2.14769
16. Crunelli V, Lüthi A. Cerebral cortex: Architecture and function. In: Shepherd GM, ed. The Synaptic Organization of the Brain. Oxford University Press, 2004, 119-163.
17. Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Pharmacol Rev,2008:60(3):243-260. doi:10.1124/pr.108.00505.
18. Macdonald RL, Olsen RW. GABA(A) receptor channels. J Biol Chem,1994:269(19):13346-13349.
19. Sigel E, Buhr A. The benzodiazepine binding site of GABA(A) receptors. Trends Pharmacol Sci,1997:18(12):425-429. doi:10.1016/S0165-6147(97)90675-1.
20. Bowery NG, Hudson AL, Price GW. GABA(A) and GABA(B) receptor site distribution in the rat central nervous system. Neuroscience,1987:20(2):365-383. doi:10.1016/0306-4522(87)90098-4.

21. Wieland HA, Luddens H, Seeburg PH. Single channel recordings from GABA(A) receptors reveal that the desensitized state is distinct from the open state. Proc Natl Acad Sci USA,1992:89(14):6595-6599. doi:10.1073/pnas.89.14.6595.
22. Supuran CT. Carbonic anhydrase inhibitors and their diverse therapeutic applications. Nat Rev Drug Discov,2008:7(2):168-181. doi:10.1038/nrd2467
23. Shaltiel G, Hulihan J. Anticonvulsant action through enhancement of GABAergic and noradrenergic neurotransmission: The dual mode of action of venlafaxine. Prog Neuropsychopharmacol Biol Psychiatry,2005:29(1):15-21. doi:10.1016/j.pnpbp.2004.09.005
24. Reddy DS, Rogawski MA. Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. J Neurosci,2002:22(9):3795-3805. doi:10.1523/JNEUROSCI.22-09-03795.2002
25. Tramontini M. Mannich bases and related compounds in organic synthesis. Synthesis,1973:12:703-775. doi:10.1055/s-1973-22374
26. Jarrahpour AA, Motamedifar M, Pakshir K, Hadi N, Zarei M. Synthesis, characterization and antimicrobial activity of some new stable Mannich bases derived from benzimidazole. Molecules,2004:9(4):144-152. doi:10.3390/90400144
27. Knoevenagel E. Condensation reactions with ammonia and amines. Ber Dtsch Chem Ges,1904:37(4):4461-4469.
28. Desai B, Mahajan S, Dhawan R, Saxena AK. Efficient synthesis of novel indole-substituted 4-oxo-4H-chromene and related compounds. Synth Commun,2005:35(18):2433-2440. doi:10.1080/00397910500196234